Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2016

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Overview
Therapeutics Development
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Products under Development by Stage of Development
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Products under Development by Therapy Area
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Products under Development by Indication
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Products under Development by Companies
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Products under Development by Universities/Institutes
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Amgen Inc.
ArQule, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
Eddingpharm
Eisai Co., Ltd.
Eli Lilly and Company
Genosco
H3 Biomedicine Inc.
Ionis Pharmaceuticals, Inc.
Johnson & Johnson
NGM Biopharmaceuticals, Inc.
Novartis AG
Principia Biopharma Inc.
Vichem Chemie Research Ltd.
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
ARQ-087 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-5878 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-709 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-9931 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDP-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erdafitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FGF-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B6527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infigratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-463588 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LQN-725 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2874455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize FGFR4 for Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-1371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
U3-1784 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Projects
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Featured News & Press Releases
Jul 04, 2016: Eisai Launches In-House Developed Novel Anticancer Agent Lenvima In Mexico
Jun 30, 2016: ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
Jun 23, 2016: ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
Jun 06, 2016: Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology Annual Meeting
May 31, 2016: City Of Hope researchers present data on BGJ398 at the American Society of Clinical Oncology’s Annual Meeting
May 24, 2016: Eisai To Present on Lenvima at 52nd Annual Meeting of the American Society of Clinical Oncology
May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma
Apr 20, 2016: Eisai Announces Non-Clinical Research Findings At Aacr 107Th Annual Meeting Regarding Combination Of Anticancer Agent Lenvatinib With Everolimus
Apr 12, 2016: Highly Anticipated New Treatment Option Now Available for Canadians with Select Type of Thyroid Cancer
Mar 09, 2016: Lenvima (lenvatinib) Now Available in Israel as Important New Treatment for People with Advanced Thyroid Cancer
Feb 25, 2016: Eisai Slams the New Cancer Drug Fund that Further Delays Patient Access to New Cancer Drug
Jan 18, 2016: U.S. FDA Accepts for Priority Review sNDA for Eisai’S Anticancer Agent Lenvatinib Seeking Approval for Renal Cell Carcinoma
Jan 12, 2016: Eisai Submits New Application In Europe For In-House Developed Anticancer Agent Lenvatinib Seeking Approval For Indication Covering Renal Cell Carcinoma
Dec 16, 2015: Lenvima (lenvatinib) Now Reimbursed for Advanced Thyroid Cancer in Sweden
Dec 15, 2015: ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Amgen Inc., H2 2016
Pipeline by ArQule, Inc., H2 2016
Pipeline by Astellas Pharma Inc., H2 2016
Pipeline by AstraZeneca Plc, H2 2016
Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
Pipeline by Blueprint Medicines Corporation, H2 2016
Pipeline by Bristol-Myers Squibb Company, H2 2016
Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Pipeline by Eddingpharm, H2 2016
Pipeline by Eisai Co., Ltd., H2 2016
Pipeline by Eli Lilly and Company, H2 2016
Pipeline by Genosco, H2 2016
Pipeline by H3 Biomedicine Inc., H2 2016
Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
Pipeline by Johnson & Johnson, H2 2016
Pipeline by NGM Biopharmaceuticals, Inc., H2 2016
Pipeline by Novartis AG, H2 2016
Pipeline by Principia Biopharma Inc., H2 2016
Pipeline by Vichem Chemie Research Ltd., H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook